This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nishimura H, Nose M, Hiai H, Minato N, Honjo T . Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 2002; 99: 12293–12297.
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537–1544.
Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–3277.
Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A . The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010; 221: 248–263.
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–3473.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.
Moskowitz CH, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). 2014. Abstract 290.
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase ii trial. J Clin Oncol 2013; 31: 4199–4206.
Villasboas JC, Ansell SM, Witzig TE . Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget (e-pub ahead of print 3 February 2016; doi:10.18632/oncotarget.7177).
Mori S, Ahmed W, Patel RD, Dohrer AL . Steroid refractory acute liver GvHD in a Hodgkin's patient after allogeneic stem transplant cell transplantation following treatment with anti PD-1 antibody, nivolumab, for relapsed disease. Biol Blood Marrow Transplant 22: S392–S393.
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2015; 51: 443–445.
Fife BT, Bluestone JA . Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166–182.
Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol 2003; 171: 1272–1277.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH . PD-1 and Its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.
Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013; 122: 3062–3073.
Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J et al. B7H1/CD80 interaction augments PD-1–dependent T Cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015; 194: 560–574.
Amarnath S, Mangus CW, Wang JCM, Wei F, He A, Kapoor V et al. The PDL1-PD1 axis converts human Th1 cells into regulatory T Cells. Sci Transl Med 2011; 3: 111ra120.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Singh, A., Porrata, L., Aljitawi, O. et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant 51, 1268–1270 (2016). https://doi.org/10.1038/bmt.2016.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.111
This article is cited by
-
Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2023)
-
The ocular graft-versus-host disease: the path from current knowledge to future managements
Eye (2023)
-
Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review
Bone Marrow Transplantation (2021)
-
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Experimental Hematology & Oncology (2019)
-
Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)